Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Allopurinol for the treatment of chronickidneydisease: a systematic review Allopurinolforthetreatmentofchronic kidneydisease:asystematicreview Nigel Fleeman, 1* Gerlinde Pilkington, 1 Yenal Dundar, 1 Kerry Dwan, 1 Angela Boland, 1 Rumona Dickson, 1 Hameed Anijeet, 2 Tom Kennedy 2 and Jason Pyatt 2 1 Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK 2 Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK *Corresponding author Declared (...) competing interests of authors: none Published June 2014 DOI: 10.3310/hta18400 Scientific summary AllopurinolforthetreatmentofCKD Health Technology Assessment 2014; Vol. 18: No. 40 DOI: 10.3310/hta18400 NIHR Journals Library www.journalslibrary.nihr.ac.ukScientificsummary Background The term chronickidneydisease (CKD) is used to describe abnormal kidney function (or structure) and is defined according to the presence or absence of kidney damage and level of kidney function. Traditionally serum
a trial with a larger number of people with chronickidneydisease. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Allopurinols; Renal Insufficiency, Chronic Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: email@example.com AccessionNumber (...) Allopurinol for the treatment of chronickidneydisease: a systematic review Allopurinol for the treatment of chronickidneydisease: a systematic review Allopurinol for the treatment of chronickidneydisease: a systematic review Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been
of ChronicKidneyDisease Horizon Scan Report 0038 March 2014 Horizon Scan Report 0035 February 2014 d) Detection of acute on chronicrenal failure and acute kidney injury (AKI) Existing Technology: Blood samples sent from GP for analysis in local hospital laboratory. Results subsequently sent back to general practice typically within 24 hours. Depending on significance of result, this may or may not be communicated to the patient by letter, telephone or in person. Benefits of POC creatinine testing (...) /nicemedia/live/12069/42117/42117.pdf NICE clinical guideline 73. 6. Mathew TH, Corso O, Ludlow M, Boyle A, Cass A, Chadban SJ, Joyner B, Shephard M, Usherwood T. Screening for chronickidneydisease in Australia: a pilot study in the community and workplace. Kidney International – Supplement. 2010; (116): S9-16. 7. Morita S, Suzuki K, Masukawa A, Ueno E. Assessing renal function with a rapid, handy, point-of-care whole blood creatinine meter before using contrast materials. Japanese Journal of Radiology
Outpatient self-dialysis programs for patients with chronicrenalconditions: clinical and cost-effectiveness, safety, and guidelines Outpatient self-dialysis programs for patients with chronicrenalconditions: clinical and cost-effectiveness, safety, and guidelines Outpatient self-dialysis programs for patients with chronicrenalconditions: clinical and cost-effectiveness, safety, and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Outpatient self-dialysis programs for patients with chronicrenalconditions: clinical and cost-effectiveness, safety, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One health technology assessment and one non-randomized study were identified regarding outpatient self-dialysis programs
KHA-CARI commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronickidneydisease Original Article Commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronickidneydisease MATTHEW A ROBERTS Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia Correspondence: Dr Matthew Roberts, Dept of Nephrology, Box Hill Hospital, Eastern Health, Level 2, 5 Arnold St (...) on cardiovascular and renal outcomes: A systematic review and meta-analysis. Plos Med. 2012; 9: e1001293. 2. Eckardt KU, Kasiske BL. Kidneydisease: Improving global outcomes. Nat. Rev. Nephrol. 2009; 5: 650–57. 3. KidneyDisease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in ChronicKidneyDisease. Kidney Int. (Suppl.) 2012; 2: 337–414. 4. Levin NW, Kotanko P, Eckardt KU et al. Blood pressure in chronickidneydisease
KHA-CARI commentary on the KDIGO Clinical Practice Guideline for lipid management in chronickidneydisease Commentary KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in ChronicKidneyDisease SUETONIA C PALMER, 1,2 GIOVANNI FM STRIPPOLI 2,3,4,5,6 and JONATHAN C CRAIG 2,3 1 Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand; 2 Cochrane Renal Group, 3 Sydney School of Public Health, University of Sydney, Sydney, New South Wales (...) cholesterol with simvastatin plus ezetimibe in patients with chronickidneydisease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181–92. 4. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 2009; 360: 1395–407. 5. Eckardt K, Kasiske B. Kidneydisease: Improving global outcomes. Nat. Rev. Nephrol. 2009; 5: 650–57. 6. KidneyDisease: Improving Global Outcomes (KDIGO
Calcimimetics for secondary hyperparathyroidism in chronickidneydisease patients. Calcimimetic agents lower abnormal serum parathyroid hormone (PTH) levels in people who have chronickidneydisease (CKD), but the benefits and harms on patient-level outcomes are uncertain. Since this review was first published in 2006 showing that evidence for calcimimetics was largely restricted to biochemical outcomes, additional studies have been conducted. This is an update of a review first published (...) in 2006.To evaluate the benefits and harms of cinacalcet on patient-level outcomes in adults with CKD.MEDLINE, EMBASE, CENTRAL and conference proceedings were searched for randomised controlled trials (RCTs) evaluating any calcimimetic against placebo or another agent in adults with CKD (persistent albuminuria > 30 mg/g with or without reduced glomerular filtration rate (GFR) (below 60 mL/min/1.73 m²)). We updated searches to 7 February 2013 including the Cochrane Renal Group's Specialised Register
and effective assessment of the patient's condition • Optimize the use of therapy to reduce disease progression, reduce symptoms of CKD, and enhance patient functionality • Minimize preventable complications and morbidity • Emphasize the use of personalized, proactive, patient-driven care December 2014 Page 5 of 117 Background Chronickidneydisease is one of the most common serious medical conditions affecting adults in the United States (US). The Centers for Disease Control and Prevention (CDC) estimate (...) to display each step in the algorithm, and arrows connect the numbered boxes indicating the order in which the steps should be followed.  Rounded rectangles represent a clinical state or condition. Hexagons represent a decision point in the guideline, formulated as a question that can be answered Yes or No. Rectangles represent an action in the process of care. December 2014 Page 12 of 117 December 2014 Page 13 of 117 Recommendations # Recommendation Strength Evaluation for ChronicKidneyDisease
A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronickidneydisease among patients on dialysis in the United Kingdom A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronickidneydisease among patients on dialysis in the United Kingdom A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronickidneydisease among patients on dialysis in the United Kingdom (...) of hyperphosphataemia, associated with chronickidneydisease, in patients who had been receiving dialysis for an average of 38.2 months. Interventions The intervention was sevelamer carbonate (6.9g/day) for the initial treatment of hyperphosphataemia. The comparator was calcium-based phosphate binders, which were those most commonly used in the UK; it was assumed that 70% of patients received calcium acetate (5.3g/day) and 30% received calcium carbonate (4.9g/day). Location/setting UK/secondary care. Methods
[Biological therapies in the treatment of anaemia associated with chronickidneydisease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents] Terapias biológicas en el tratamiento de la anemia asociada a insuficiencia renal crónica: eficacia y seguridad comparada entre los agentes estimuladores de la eritropoyesis [Biological therapies in the treatment of anaemia associated with chronickidneydisease: a comparison of efficacy and safety of different (...) erythropoiesis-stimulating agents] Terapias biológicas en el tratamiento de la anemia asociada a insuficiencia renal crónica: eficacia y seguridad comparada entre los agentes estimuladores de la eritropoyesis [Biological therapies in the treatment of anaemia associated with chronickidneydisease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents] Abdel–Kader Martín, L; Castillo Muñoz, MA; Ubago Pérez, R; Vega Coca, MD; Rodríguez López, R Record Status This is a bibliographic
Effects of intensive blood pressure lowering on the progression of chronickidneydisease: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Evaluation and management of chronickidneydisease: synopsis of the kidneydisease: improving global outcomes 2012 clinical practice guideline. The KidneyDisease: Improving Global Outcomes (KDIGO) organization developed clinical practice guidelines in 2012 to provide guidance on the evaluation, management, and treatment of chronickidneydisease (CKD) in adults and children who are not receiving renal replacement therapy.The KDIGO CKD Guideline Development Work Group defined the scope
Chronickidneydisease and cardiovascular risk: epidemiology, mechanisms, and prevention. Since the first description of the association between chronickidneydisease and heart disease, many epidemiological studies have confirmed and extended this finding. As chronickidneydisease progresses, kidney-specific risk factors for cardiovascular events and disease come into play. As a result, the risk for cardiovascular disease is notably increased in individuals with chronickidneydisease. When (...) adjusted for traditional cardiovascular risk factors, impaired kidney function and raised concentrations of albumin in urine increase the risk of cardiovascular disease by two to four times. Yet, cardiovascular disease is frequently underdiagnosed and undertreated in patients with chronickidneydisease. This group of patients should, therefore, be acknowledged as having high cardiovascular risk that needs particular medical attention at an individual level. This view should be incorporated
Chronickidneydisease: global dimension and perspectives. Chronickidneydisease is defined as a reduced glomerular filtration rate, increased urinary albumin excretion, or both, and is an increasing public health issue. Prevalence is estimated to be 8-16% worldwide. Complications include increased all-cause and cardiovascular mortality, kidney-disease progression, acute kidney injury, cognitive decline, anaemia, mineral and bone disorders, and fractures. Worldwide, diabetes mellitus (...) is the most common cause of chronickidneydisease, but in some regions other causes, such as herbal and environmental toxins, are more common. The poorest populations are at the highest risk. Screening and intervention can prevent chronickidneydisease, and where management strategies have been implemented the incidence of end-stage kidneydisease has been reduced. Awareness of the disorder, however, remains low in many communities and among many physicians. Strategies to reduce burden and costs related